Results 101 to 110 of about 18,827 (200)

Process for the preparation of Palbociclib

The present disclosure provides a process for the preparation of controlled particle size and specific surface area of crystalline form-A of Palbociclib and its process for the preparation. Palbociclib is represented by the following structural formula-1.
, MSN Laboratories Private Limited, R&D Center; Srinivasan Thirumalai Rajan; . Irukuvajjula Venkata Subrahmanya Vithal, Kesari Sai Manoj Krishna and Bhatraju Daveedu
core   +1 more source

Cyclin dependent kinase 4/6 inhibitor palbociclib synergizes with BCL2 inhibitor venetoclax in experimental models of mantle cell lymphoma without RB1 deletion

Experimental Hematology & Oncology
Background Mantle cell lymphoma (MCL) is a chronically relapsing malignancy with deregulated cell cycle progression. We analyzed efficacy, mode of action, and predictive markers of susceptibility to palbociclib, an approved CDK 4/6 inhibitor, and its ...
Diana Malarikova, Radek Jorda, Kristyna Kupcova, Jana Senavova, Alexandra Dolnikova, Eva Pokorna, Dmitry Kazantsev, Kristina Nozickova, Dana Sovilj, Celine Bellanger, David Chiron, Ladislav Andera, Vladimir Krystof, Miroslav Strnad, Karel Helman, Magdalena Klanova, Marek Trneny, Ondrej Havranek, Pavel Klener   +18 more
doaj   +1 more source

Cathepsin V (CTSV) Shapes the Epigenetic–Immune Landscape of Bladder Cancer and Emerges as a Noninvasive Biomarker

International Journal of Urology, Volume 33, Issue 9, September 2026.
ABSTRACT Objective The aim of this study was to perform a comprehensive characterization of CTSV regulation in bladder cancer (BC) and its association with clinicopathological features, prognosis, and tumor stroma modulation using multi‐omics databases.
Wallax Augusto Silva Ferreira, Fabio Albuquerque Marchi, Glauco Akelinghton Freire Vitiello, Rolando André Rios Villacis, Ana Paula Drummond Rodrigues, Edivaldo Herculano Correa de Oliveira   +5 more
wiley   +1 more source

Comparative Efficacy of BTK Inhibitors in Treatment‐Naïve and Relapsed/Refractory Mantle Cell Lymphoma: A Systematic Review and Meta‐Analysis

Journal of Cellular and Molecular Medicine, Volume 30, Issue 17, September 2026.
ABSTRACT Bruton tyrosine kinase inhibitors (BTKis) have been employed in the treatment of mantle cell lymphoma (MCL). However, direct comparisons of ibrutinib, zanubrutinib, and acalabrutinib across treatment‐naïve (TN) and relapsed/refractory (R/R) MCL remain limited. This meta‐analysis was intended to evaluate their efficacy, addressing critical gaps
Fangfei Xu, Xiuping Zou, Yulin Yang, Kuangguo Zhou, Wei Huang   +4 more
wiley   +1 more source

Deciphering the Dysregulated Pathways and Candidate Therapeutic Compounds for Primary Ovarian Cancer Using Whole Transcriptomics Data and Next Generation Knowledge Discovery Strategies

Journal of Cellular and Molecular Medicine, Volume 30, Issue 18, September 2026.
ABSTRACT Ovarian cancer (OC) is a type of gynaecological cancer with a higher mortality rate due to diagnosis at an advanced stage and limited treatment options. This study aimed to leverage transcriptomic data to identify cellular and molecular pathways and potential anti‐cancer compounds that specifically target primary invasive epithelial ovarian ...
Peter Natesan Pushparaj, Kalamegam Gauthaman, Alaa G. Alahmadi, Reem Nabil Hassan, Hind A. Alkhatabi, Ammar AL‐Farga   +5 more
wiley   +1 more source

Preclinical evaluation of palbociclib on newly established preclinical models of nasopharyngeal carcinoma (NPC)

, 2020
The efficacy of a selective CDK4/6 inhibitor (palbociclib) was evaluated in various preclinical models of nasopharyngeal carcinoma (NPC) including three NPC cell line (two newly established) and three newly established patient-derived xenografts (PDXs ...
Xue, Zhichao, 薛志超
core  

Comparative Response of Canine and Human Osteosarcoma Tumour Cell Lines to Molecularly Targeted Anticancer Agents at Clinically Relevant Exposures With Analysis of Genomic Biomarkers

Veterinary and Comparative Oncology, Volume 24, Issue 3, Page 532-544, September 2026.
ABSTRACT Osteosarcoma (OSA) is a primary bone tumour occurring in children but is also prevalent in large breed dogs. Canine OSA (cOSA) has long been viewed as analogous to human OSA (hOSA) with cOSA serving as a surrogate for development of therapeutic approaches to treat the rarer human form.
Daniel L. Gustafson, Kala A. Early, Maritza A. Morales, Klaudia A. Poplawski, Sunetra Das, Dawn L. Duval   +5 more
wiley   +1 more source

Palbociclib exposure in relation to efficacy and toxicity in patients with advanced breast cancer [PDF]

Background: Data on exposure–response or exposure–toxicity relationships of cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) are limited and inconclusive.
Steeghs, N., Siebinga, H., Huitema, A. D.R., Jager, A., Buijs, S. M., Braal, C. L., Wortelboer, N., Koolen, S. L.W., Mathijssen, R. H.J.; id_orcid, Oomen-de Hoop, E.; id_orcid, Mohmaed Ali, M. I., Sonke, G. S., Konings, I. R., van Ommen-Nijhof, A.   +13 more
core   +1 more source

Identification of Novel Therapeutic Agent Candidates Through High Throughput Screening With Chemical Library Based on Molecular Subclassification in Canine Histiocytic Sarcoma Cell Lines

Veterinary and Comparative Oncology, Volume 24, Issue 3, Page 554-567, September 2026.
ABSTRACT Effective chemotherapy for canine histiocytic sarcoma (CHS) has yet to be established. In our previous study, CHS cell lines were subclassified into two groups based on their gene expression profiles: Group A and Group B. This study aimed to identify novel therapeutic agents that are effective against each CHS subgroup, and we performed high ...
Hiroki Sakuma, Hirotaka Tomiyasu, Mari Takamiya, Yuko Goto‐Koshino, Atsushi Tsukamoto, Makoto Bonkobara, Masaru Okuda   +6 more
wiley   +1 more source

Reversible Coordination Modes in Piperazine‐Based Ru(II)‐p‐Cymene Acylthiourea Complexes: Modulating DNA Groove Binding for Selective Antimelanoma Activity

ChemMedChem, Volume 21, Issue 16, 27 August 2026.
Piperazine‐based monodentate and S,N‐bidentate Ru(II)‐p‐cymene complexes were synthesized through distinct coordination strategies and evaluated for antimelanoma activity. Among the investigated compounds, the S,N‐bidentate complex 2b exhibited significantly enhanced cytotoxicity (IC50 = 6.1 ± 0.8 ) against melanoma cells, particularly the A375 cell ...
Amir Karim, Xin Wang, Yu‐Ting Chu, Rahimeh Eshaghi Malekshah, En‐De Shu, Najeeb Ullah, Chien‐Chih Chiu, Ching‐Ming Chien, Sodio C. N. Hsu   +8 more
wiley   +1 more source